<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04339075</url>
  </required_header>
  <id_info>
    <org_study_id>2019/2749</org_study_id>
    <nct_id>NCT04339075</nct_id>
  </id_info>
  <brief_title>Registry to Investigate the Efficacy and Safety of VenaBlock VeIn SEaling System for VaRicose Veins in SingApore</brief_title>
  <acronym>RIVIERA</acronym>
  <official_title>Registry to Investigate the Efficacy and Safety of VenaBlock VeIn SEaling System for VaRicose Veins in SingApore</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Singapore General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Singapore General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the efficacy of the Venablock©Vein Sealing System (VBVS) for the treatment of lower
      extremity superficial truncal veins in a real-world clinical setting in a multi-racial Asian
      population in Singapore.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of the Registy to Investigate the Eficacy and Safety of Venablock©Vein Sealing
      System for Varicose Veins in Singapore (RIVERIA), is to investigare the performance of
      cyanoacrylate glue closure (CAC) using this device, in which multiple incompetent superficial
      saphenous truncal veins (great saphenous (GSV), short saphenous vein (SSV), anterior
      accessorysaphenous vein (AASV) will be treated at the same setting, and compression stockings
      will not be used postoperatively. The inclusion criteria for this studywill be liberalized,
      and veins up to 12mm in diameter will be treated. As such,RIVIERAwill be the first
      prospective trial conducted in Asia on a predominantlyAsian cohort of patients to report on
      the performance of Venablock©for blocking incompetent truncal veins. This
      studyspecificallyfocuses on the initial technical outcomes, safety, anatomical occlusion, and
      patient experience after treatmentwith Venablock©with broader inclusion of patients than
      previous caucasian based trials.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 1, 2019</start_date>
  <completion_date type="Anticipated">October 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Technical Success at time of procedure</measure>
    <time_frame>Immediately post-op</time_frame>
    <description>Occlusion of treated vein post-procedure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in anatomy of treated vessel</measure>
    <time_frame>2 weeks, 3 months, 6 months, 12 months post-procedure</time_frame>
    <description>Anatomical Success as measured at each timepoint using ultrasound to ensure occlusion of treated vessel. Recurrence or treatment failure will be defined as a re-opening of a segment &gt; 5cm in length.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Score using the EQ-5D questionnaire</measure>
    <time_frame>2 weeks, 3 months, 6 months, 12 months post-procedure</time_frame>
    <description>EQ5D is used to assess quality of life based on Mobility, Self-Care, Usual Activities, Pain/Discomfort and Anxiety, rated at 5 levels: no problems, slight problems, moderate problems, severe problems, unable to perform activity. Inputs from this questionnaire is used to observe for changes in quality of life overtime.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Score using the Chronic Venous Insufficiency Questionnaire (CIVIQ)</measure>
    <time_frame>2 weeks, 3 months, 6 months, 12 months post-procedure</time_frame>
    <description>CIVIQ is a questionnaire based on three dimensions - pain, physical and psychological, based on a scale from 1 to 5 (no trouble, slight, moderate, considerable, severe). Based on inputs, Global Index Score (GIS) will be tabulated, ranging for 0 to 100 - the higher the value, the poorer the quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life score using the Aberdeen Varicose Vein Questionnaire (AVVQ)</measure>
    <time_frame>2 weeks, 3 months, 6 months, 12 months post-procedure</time_frame>
    <description>To measure health status of varicose veins patients based on symptoms and impact on daily activities. A total score ranging from 0 to 100 will be tabulated, with 100 being worst quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Change using Venous Clinical Severity Score (VCSS)</measure>
    <time_frame>2 weeks, 3 months, 6 months, 12 months post-procedure</time_frame>
    <description>VCSS evaluates the severity of hallmarks of venous disease - 0 (none), 1 (mild), 2 (moderate), 3 (severe).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Score</measure>
    <time_frame>First 10 days post-procedure</time_frame>
    <description>Using a numerical rating scale, which ranges from 0 (no pain) to 10 (severe pain)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time taken to return to work and normal activities</measure>
    <time_frame>Recorded 10 days post-procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occlusion rates</measure>
    <time_frame>2 weeks, 3 months, 6 months, 12 months post-procedure</time_frame>
    <description>Duplex ultrasound performed at specific timepoints to ensure that treated vein is occluded</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient satisfaction with treatment: survey</measure>
    <time_frame>2 weeks, 3 months, 6 months, 12 months post-procedure</time_frame>
    <description>A short survey to assess patient satisfaction and if there are any observed improvement in terms of appearance and symptoms post-procedure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost effectiveness of the intervention</measure>
    <time_frame>12 months post-procedure</time_frame>
    <description>to evaluate the cost involved with the procedure performed</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">30</enrollment>
  <condition>Varicose Veins</condition>
  <condition>Venous Reflux</condition>
  <condition>Chronic Venous Insufficiency</condition>
  <arm_group>
    <arm_group_label>Venablock</arm_group_label>
    <description>Patients that have undergone Venablock treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaires</intervention_name>
    <description>Questionnaires to access the quality of life (EQ5D, VCSS, CVVQ, CIVIQ, Patient satisfaction survery)</description>
    <arm_group_label>Venablock</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who will be undergoing Venablock© as a treatment for their varicose veins /
        chronic venous insufficiency
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age &gt; 21 years old and ability to understand the requirements of the study and to
             provide informed consent

          2. C2-C6 varicose veins/CVI (CEAP Class 1 patients will be excluded)

          3. Symptomatic primary GSV,SSV or AASV incompetence, with reflux &gt; 0.5 seconds on colour
             Duplex, including one or more of the following symptoms: aching, throbbing, heaviness,
             fatigue, pruritus, night cramps, restlessness, generalized pain or discomfort,
             swelling

          4. Patients who had GSV, SSV or AASV diameters of 3mm to 12mm in the standing position

        Exclusion Criteria:

          1. Current DVT or history of DVT

          2. Pregnant patients

          3. Arterial disease (ABPI&lt;0.8)

          4. Sepsis

          5. Patient who are unwilling to participate

          6. Inability or unwillingness to complete the time-point questionnaires

          7. Adverse reaction to sclerosant or cyanoacrylate previously

          8. Multiple drug allergies

          9. Previous intervention with the VenaSeal cyanoacrylate glue closure system

         10. Severely tortuous GSV, SSV or AASV

         11. Life expectancy &lt; 1 year

         12. Active treatment for malignancy other than non-melanoma skin cancer

         13. Current, regular use of systemic anticoagulation (e.g., warfarin, heparin)

         14. Daily use of narcotic analgesia or NSAIDS to control pain associated with venous
             disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>Singapre General Hospital</name>
      <address>
        <city>Singapore</city>
        <zip>169608</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <reference>
    <citation>Nesbitt C, Bedenis R, Bhattacharya V, Stansby G. Endovenous ablation (radiofrequency and laser) and foam sclerotherapy versus open surgery for great saphenous vein varices. Cochrane Database Syst Rev. 2014 Jul 30;(7):CD005624. doi: 10.1002/14651858.CD005624.pub3. Review.</citation>
    <PMID>25075589</PMID>
  </reference>
  <reference>
    <citation>Siribumrungwong B, Noorit P, Wilasrusmee C, Attia J, Thakkinstian A. A systematic review and meta-analysis of randomised controlled trials comparing endovenous ablation and surgical intervention in patients with varicose vein. Eur J Vasc Endovasc Surg. 2012 Aug;44(2):214-23. doi: 10.1016/j.ejvs.2012.05.017. Epub 2012 Jun 15. Review.</citation>
    <PMID>22705163</PMID>
  </reference>
  <reference>
    <citation>Darwood RJ, Theivacumar N, Dellagrammaticas D, Mavor AI, Gough MJ. Randomized clinical trial comparing endovenous laser ablation with surgery for the treatment of primary great saphenous varicose veins. Br J Surg. 2008 Mar;95(3):294-301. doi: 10.1002/bjs.6101.</citation>
    <PMID>18278775</PMID>
  </reference>
  <reference>
    <citation>Rasmussen LH, Lawaetz M, Bjoern L, Vennits B, Blemings A, Eklof B. Randomized clinical trial comparing endovenous laser ablation, radiofrequency ablation, foam sclerotherapy and surgical stripping for great saphenous varicose veins. Br J Surg. 2011 Aug;98(8):1079-87. doi: 10.1002/bjs.7555.</citation>
    <PMID>21725957</PMID>
  </reference>
  <reference>
    <citation>Marsden G, Perry M, Kelley K, Davies AH; Guideline Development Group. Diagnosis and management of varicose veins in the legs: summary of NICE guidance. BMJ. 2013 Jul 24;347:f4279. doi: 10.1136/bmj.f4279.</citation>
    <PMID>23884969</PMID>
  </reference>
  <reference>
    <citation>Shepherd AC, Gohel MS, Brown LC, Metcalfe MJ, Hamish M, Davies AH. Randomized clinical trial of VNUS ClosureFAST radiofrequency ablation versus laser for varicose veins. Br J Surg. 2010 Jun;97(6):810-8. doi: 10.1002/bjs.7091.</citation>
    <PMID>20473992</PMID>
  </reference>
  <reference>
    <citation>Shepherd AC, Gohel MS, Lim CS, Hamish M, Davies AH. Pain following 980-nm endovenous laser ablation and segmental radiofrequency ablation for varicose veins: a prospective observational study. Vasc Endovascular Surg. 2010 Apr;44(3):212-6. doi: 10.1177/1538574409359337. Epub 2010 Feb 11.</citation>
    <PMID>20150227</PMID>
  </reference>
  <reference>
    <citation>Rabe E, Otto J, Schliephake D, Pannier F. Efficacy and safety of great saphenous vein sclerotherapy using standardised polidocanol foam (ESAF): a randomised controlled multicentre clinical trial. Eur J Vasc Endovasc Surg. 2008 Feb;35(2):238-45. Epub 2007 Nov 7.</citation>
    <PMID>17988905</PMID>
  </reference>
  <reference>
    <citation>Morrison N, Gibson K, McEnroe S, Goldman M, King T, Weiss R, Cher D, Jones A. Randomized trial comparing cyanoacrylate embolization and radiofrequency ablation for incompetent great saphenous veins (VeClose). J Vasc Surg. 2015 Apr;61(4):985-94. doi: 10.1016/j.jvs.2014.11.071. Epub 2015 Jan 31.</citation>
    <PMID>25650040</PMID>
  </reference>
  <reference>
    <citation>Tang TY, Kam JW, Gaunt ME. ClariVein® - Early results from a large single-centre series of mechanochemical endovenous ablation for varicose veins. Phlebology. 2017 Feb;32(1):6-12. doi: 10.1177/0268355516630154. Epub 2016 Jul 9.</citation>
    <PMID>26908638</PMID>
  </reference>
  <reference>
    <citation>Vanlangenhove P, De Keukeleire K, Everaert K, Van Maele G, Defreyne L. Efficacy and safety of two different n-butyl-2-cyanoacrylates for the embolization of varicoceles: a prospective, randomized, blinded study. Cardiovasc Intervent Radiol. 2012 Jun;35(3):598-606. doi: 10.1007/s00270-011-0188-9. Epub 2011 Jun 3.</citation>
    <PMID>21638147</PMID>
  </reference>
  <reference>
    <citation>Brothers MF, Kaufmann JC, Fox AJ, Deveikis JP. n-Butyl 2-cyanoacrylate--substitute for IBCA in interventional neuroradiology: histopathologic and polymerization time studies. AJNR Am J Neuroradiol. 1989 Jul-Aug;10(4):777-86.</citation>
    <PMID>2505505</PMID>
  </reference>
  <reference>
    <citation>Ovalı C, Sevin MB. Twelve-month efficacy and complications of cyanoacrylate embolization compared with radiofrequency ablation for incompetent great saphenous veins. J Vasc Surg Venous Lymphat Disord. 2019 Mar;7(2):210-216. doi: 10.1016/j.jvsv.2018.10.019. Epub 2019 Jan 14.</citation>
    <PMID>30655108</PMID>
  </reference>
  <reference>
    <citation>Yavuz T, Acar AN, Aydın H, Ekingen E. A retrospective study of a new n-butyl-2-cyanoacrylate glue ablation catheter incorporated with application guiding light for the treatment of venous insufficiency: Twelve-month results. Vascular. 2018 Oct;26(5):547-555. doi: 10.1177/1708538118770548. Epub 2018 Apr 11.</citation>
    <PMID>29642798</PMID>
  </reference>
  <reference>
    <citation>Lee Q, Gibson K, Chan SL, Rathnaweera HP, Chong TT, Tang TY. A comparison between Caucasian and Asian superficial venous anatomy and reflux patterns - Implications for potential precision endovenous ablation therapy. Phlebology. 2020 Feb;35(1):39-45. doi: 10.1177/0268355519845984. Epub 2019 Apr 29.</citation>
    <PMID>31032714</PMID>
  </reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 6, 2020</study_first_submitted>
  <study_first_submitted_qc>April 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 9, 2020</study_first_posted>
  <last_update_submitted>April 8, 2020</last_update_submitted>
  <last_update_submitted_qc>April 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Endovenous Ablation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Venous Insufficiency</mesh_term>
    <mesh_term>Varicose Veins</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 29, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/75/NCT04339075/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>September 16, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/75/NCT04339075/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

